Infliximab to Treat Severe Paradoxical Reaction in HIV-Negative Tuberculous Meningoencephalitis

Author(s): Tiphaine Goulenok, MD1,2; Augustin Gaudemer, MD2,3; Diane Rouzaud, MD1,2; Marie-Paule Chauveheid, MD1,2; Jean Francois Alexandra, MD1,2; Karim Sacre, MD, PhD1,2,4; Thomas Papo, MD1,2,4

Corresponding Author: Tiphaine Goulenok
tiphaine.goulenok@aphp.fr

Neurology® Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.

Contributions: 
Tiphaine Goulenok: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data 
Augustin Gaudemer: Major role in the acquisition of data; Analysis or interpretation of data 
Diane Rouzaud: Major role in the acquisition of data; Study concept or design 
Marie-Paule Chauveheid: Major role in the acquisition of data; Study concept or design 
Jean Francois Alexandra: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data 
Karim Sacre: Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design 
Thomas Papo: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data

Number of characters in title: 10

Abstract Word count:

Word count of main text: 92

References: 2

Figures: 1

Tables: 0

Neuroimage Legend Count: 49

Supplemental: Patient Consent for publication Author agreement


Study Funding: The authors report no targeted funding

Disclosures: The authors report no disclosure relevant to the manuscript.
Tuberculous meningoencephalitis (TBM) was diagnosed in a 33 years old HIV-negative patient. CSF culture was positive for drug-susceptible mycobacterium tuberculosis and anti-TB therapy associated with steroids were started. After 3 months, brain MRI showed a worsening of the basal meningeal enhancement while the patient complained of new headaches. CSF analysis demonstrated pleocytosis (100 cells/mm$^3$), with an increased protein count (2580 mg/dL); CSF culture and viral panel were negative. The worsening was considered due to immune reconstitution inflammatory syndrome (IRIS) and Infliximab was started leading to dramatic clinical and imaging improvement (Figure 1).

References


Figure title

Sequential brain MRI and treatments for severe paradoxical reaction in tuberculous meningoencephalitis

Legends

Longitudinal follow-up on brain MRI (axial reconstruction of contrast-enhanced 3D GE T1-weighted). Basilar meningitis clear-cut worsening with dramatic improvement following infliximab treatment. At 3 months, we notice a proximal vascular involvement with a spread to perimesencephalic and ambient cisterns.

I; isoniazid, R; Rifampicin, P; Pyrazinamide, E; Ethambutol, MP; Methylprednisolone
<table>
<thead>
<tr>
<th>TB therapy</th>
<th>I/R/P/E</th>
<th>I/R</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prednisone (mg/d)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MP pulse</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infliximab</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(5 mg/kg)</td>
<td></td>
<td>120</td>
</tr>
<tr>
<td></td>
<td></td>
<td>60</td>
</tr>
<tr>
<td></td>
<td></td>
<td>30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5</td>
</tr>
</tbody>
</table>
Infliximab to Treat Severe Paradoxical Reaction in HIV-Negative Tuberculous Meningoencephalitis
Tiphaine Goulenok, Augustin Gaudemer, Diane Rouzaud, et al.
Neurology published online November 2, 2021
DOI 10.1212/WNL.0000000000013047

This information is current as of November 2, 2021